2-(2-Chloroethyl)benzimidazole

Other bromoethylarenes were prepared according to literature procedures as shown in the schemes below. Additional bromoethylindoles were prepared by Fischer-type indole synthesis followed by bromination (Campos, K.R. et al . 2004; Mewshaw, R.R. et al . 2004) (Scheme 16), acylation of substituted indoles with oxalyl chloride (Woodward, R.B. et al . 1958) followed by reduction (Feldman, et al . 1986) and bromination (Scheme 17) . 3- (2-bromoethyl) benzofuran (Kozikowski, A. P. et al . 2007; Tomaszewski, Z. et al . 1992) and 3- (2-bromoethyl ) benzothiophene were prepared according to the protocols in Scheme 18. 3-indolylacetaldehyde was prepared by Parikh-Doering oxidation of tryptophol (Sugawara, S. et al . 2009), 3- ( 2-oxoethyl ) -lH-indole-2-carboxylate was prepared from 2- (carboethoxy) indole via literature procedures (Buechi, G. et al . 1977; Vega, A.M. et al . 1981) , and 2- (2-chloroethyl ) benzimidazole was prepared by condensation of o-phenylenediamine and 3- chloropropionic acid (Cowart, M. et al . 2004) (Scheme 19) .General procedure: A mixture of 73 norfloxacin (1.920g, 0.006mol), 97 potassium carbonate (0.830g, 0.006mol) and 98 potassium iodide (0.100g, 0.006mol) in 99 acetonitrile (100mL) was stirred at 50C for 1h. After the mixture was cooled to room temperature, compound 8a (1.000g, 0.006mol) was added. The reaction mixture was then heated at 50C for 3h. After the reaction was completed (monitored by TLC, chloroform/methanol (50/1, V/V)), the reaction was cooled to room temperature and treated with 90 formic acid to adjust the pH value to 5.5-6.5. After the acetonitrile was removed under reduced pressure, the mixture was purified by flash silica gel column eluting with chloroform/methanol (60/1, V/V) to give the pure target 100 compound 13a as white power (1.120g). Yield: 41.7%.General procedure: A mixture of 73 norfloxacin (1.920g, 0.006mol), 97 potassium carbonate (0.830g, 0.006mol) and 98 potassium iodide (0.100g, 0.006mol) in 99 acetonitrile (100mL) was stirred at 50C for 1h. After the mixture was cooled to room temperature, compound 8a (1.000g, 0.006mol) was added. The reaction mixture was then heated at 50C for 3h. After the reaction was completed (monitored by TLC, chloroform/methanol (50/1, V/V)), the reaction was cooled to room temperature and treated with 90 formic acid to adjust the pH value to 5.5-6.5. After the acetonitrile was removed under reduced pressure, the mixture was purified by flash silica gel column eluting with chloroform/methanol (60/1, V/V) to give the pure target 100 compound 13a as white power (1.120g). Yield: 41.7%.General procedure: 2-(2-Aminoethyl)-N-[(3-fluoropyridin-2-yl)methyl]-1 , 3-thiazole-4-carboxamide dihydrochloride (103) (2.0 g, 3.96 mmol) was added to a solution of 2-(2-chloroethyl)-1 H-1 , 3-benzodiazole hydrochbride (1.12 g, 5.15 mmol) and DIPEA (10.6 ml, 59.45 mmol) in DMF (60 ml). The reaction mixture was allowed to stir at 3GC for 6 d (reaction was monitored by LCMS). The mixture was concentrated in vacuo and the residue was neutralised using sat. NaHC03 (aq). The aqueous layer was extracted using 4: 1 CHCb / 1 PA (4 x 100 ml) and the combined organic layers were dried (MgS04), filtered and evaporated in vacuo. The crude residue was purified by flash column chromatography (kp-NH, eluting with a gradient of 60-100% EtOAc / heptane followed by 0-20% MeOH / EtOAc) follow by neutral reverse-phase column chromatography (gradient elution 0-60% MeCN / water) to give the title compound (0.173 g, 10%) as a yellow oil. 1 H-NMR (Methanol-d4, 500 MHz): d[ppm]= 8.31 (d, J = 4.6 Hz, 1 H), 8.02 (s, 1 H), 7.57 (t, J = 9.1 Hz, 1 H), 7.45 - 7.40 (m, 2H), 7.36 (dd, J = 8.6, 4.3 Hz, 1 H), 7.17 (dd, J = 6.0, 3.2 Hz, 2H), 4.68 (s, 2H), 3.26 (d, J = 6.8 Hz, 2H), 3.15 - 3.07 (m, 6H) HPLCMS (Method D): [m/z]: 425.1 [M+H]+In a similar fashion to general procedure 7, -(pyridin-2-ylmethyl)-4H, 5H, 6H, 7H-thieno[2, 3-c]pyridine-3- carboxamide (450) (65 mg, 0.24 mmol), K2C03 (49 mg, 0.36 mmol) and 2-(2-chloroethyl)-1 H- benzimidazole (47 mg, 0.26 mmol) in acetone (3 ml) at room temperature for 24 h, followed by the addition of DMF (5 ml), Nal (39 mg, 0.26 mmol), DIPEA (0.16 ml, 0.95 mmol) and 2-(2-chloroethyl)-1 H- benzimidazole (94 mg, 0.52 mmol) at room temperature for 72 h, gave the title compound (9 mg, 9%) as an orange solid after purification by basic prep-HPLC. 1 H-NMR (DMSO-d6, 500 MHz): d[ppm]= 12.17 (s, 1 H), 8.75 (t, J = 6.0 Hz, 1 H), 8.50 (d, J = 4.2 Hz, 1 H), 7.94 (s, 1 H), 7.75 (td, J = 7.7, 1.8 Hz, 1 H), 7.46 (s, 2H), 7.31 (d, J = 7.8 Hz, 1 H), 7.28- 7.23 (m, 1 H), 7.10 (dd, J = 6.0, 3.1 Hz, 2H), 4.48 (d, J = 6.0 Hz, 2H), 3.71 (s, 2H), 3.05 (t, J = 7.2 Hz, 2H), 2.96 (t, J = 7.2 Hz, 2H), 2.82 (d, J = 5.3 Hz, 2H), 2.75 (t, J = 5.7 Hz, 2H) HPLCMS (Method B): [m/z]: 418.2 [M+H]+General procedure: 2-(2-Aminoethyl)-N-[(3-fluoropyridin-2-yl)methyl]-1 , 3-thiazole-4-carboxamide dihydrochloride (103) (2.0 g, 3.96 mmol) was added to a solution of 2-(2-chloroethyl)-1 H-1 , 3-benzodiazole hydrochbride (1.12 g, 5.15 mmol) and DIPEA (10.6 ml, 59.45 mmol) in DMF (60 ml). The reaction mixture was allowed to stir at 3GC for 6 d (reaction was monitored by LCMS). The mixture was concentrated in vacuo and the residue was neutralised using sat. NaHC03 (aq). The aqueous layer was extracted using 4: 1 CHCb / 1 PA (4 x 100 ml) and the combined organic layers were dried (MgS04), filtered and evaporated in vacuo. The crude residue was purified by flash column chromatography (kp-NH, eluting with a gradient of 60-100% EtOAc / heptane followed by 0-20% MeOH / EtOAc) follow by neutral reverse-phase column chromatography (gradient elution 0-60% MeCN / water) to give the title compound (0.173 g, 10%) as a yellow oil. 1 H-NMR (Methanol-d4, 500 MHz): d[ppm]= 8.31 (d, J = 4.6 Hz, 1 H), 8.02 (s, 1 H), 7.57 (t, J = 9.1 Hz, 1 H), 7.45 - 7.40 (m, 2H), 7.36 (dd, J = 8.6, 4.3 Hz, 1 H), 7.17 (dd, J = 6.0, 3.2 Hz, 2H), 4.68 (s, 2H), 3.26 (d, J = 6.8 Hz, 2H), 3.15 - 3.07 (m, 6H) HPLCMS (Method D): [m/z]: 425.1 [M+H]+In a similar fashion using general procedure 7, 1-(2-aminoethyl)-N-[(3-chloropyridin-2-yl)methyl]-1H- pyrazole-4-carboxamide dihydrochloride (261) (0.45 g, 1.28 mmol), 2-(2-chloroethyl)-1H-benzimidazole (0.28 g, 1.53 mmol) and DIPEA (3.3 ml, 19.14 mmol) in DMF (7 ml) at room temperature for 66 h, then heated to 40C for 90 h, gave the title compound (112 mg, 21%) as a colourless film after purification by flash column chromatography (kp-NH, eluting with a gradient of 0-10% MeOH / DCM) followed by basic prep-HPLC. 1H-NMR (DMSO-d6, 500 MHz): d[ppm]= 12.10 (s, 1H), 8.52-8.44 (m, 2H), 8.22 (s, 1H), 7.92 (dd, J = 8.1, 1.4 Hz, 1H), 7.90 (s, 1H), 7.55-7.38 (br m, 2H), 7.37 (dd, J = 8.1, 4.7 Hz, 1H), 7.13- 7.07 (m, 2H), 4.63 (d, J = 5.7 Hz, 2H), 4.20 (t, J = 6.2 Hz, 2H), 2.99- 2.93 (m, 4H), 2.93 - 2.89 (m, 2H) HPLCMS (Method C): [m/z]: 424.1 [M+H]General procedure: 2-(2-Aminoethyl)-N-[(3-fluoropyridin-2-yl)methyl]-1 , 3-thiazole-4-carboxamide dihydrochloride (103) (2.0 g, 3.96 mmol) was added to a solution of 2-(2-chloroethyl)-1 H-1 , 3-benzodiazole hydrochbride (1.12 g, 5.15 mmol) and DIPEA (10.6 ml, 59.45 mmol) in DMF (60 ml). The reaction mixture was allowed to stir at 3GC for 6 d (reaction was monitored by LCMS). The mixture was concentrated in vacuo and the residue was neutralised using sat. NaHC03 (aq). The aqueous layer was extracted using 4: 1 CHCb / 1 PA (4 x 100 ml) and the combined organic layers were dried (MgS04), filtered and evaporated in vacuo. The crude residue was purified by flash column chromatography (kp-NH, eluting with a gradient of 60-100% EtOAc / heptane followed by 0-20% MeOH / EtOAc) follow by neutral reverse-phase column chromatography (gradient elution 0-60% MeCN / water) to give the title compound (0.173 g, 10%) as a yellow oil. 1 H-NMR (Methanol-d4, 500 MHz): d[ppm]= 8.31 (d, J = 4.6 Hz, 1 H), 8.02 (s, 1 H), 7.57 (t, J = 9.1 Hz, 1 H), 7.45 - 7.40 (m, 2H), 7.36 (dd, J = 8.6, 4.3 Hz, 1 H), 7.17 (dd, J = 6.0, 3.2 Hz, 2H), 4.68 (s, 2H), 3.26 (d, J = 6.8 Hz, 2H), 3.15 - 3.07 (m, 6H) HPLCMS (Method D): [m/z]: 425.1 [M+H]+In a similar fashion using general procedure 7, 1-(2-aminoethyl)-N-[(3-fluoropyridin-2-yl)methyl]-1 H- pyrazole-4-carboxamide dihydrochloride (260) (0.7 g, 2.08 mmol), 2-(2-chloroethyl)-1 H-benzimidazole (0.451 g, 2.499 mmol) and DIPEA (5.4 ml, 31.23 mmol) in DMF (15 ml) at 3(?C for 6 d gave the product as the free base (63 mg) after purification by silica column chromatography (kpNH, eluting with a gradient of 0-40% MeOH / EtOAc) followed by basic prep-HPLC. The freebase product was dissolved in MeOH (3 ml) and 12 M HCI (2 ml) at room temperature for 2 h to give the title compound (65 mg, 5.6%) as a brown solid. 1H-NMR (Methanol-d4, 500 MHz): d[ppm]= 8.46 (s, 1H), 8.25 (s, 1H), 8.01 (s, 1H), 7.81 (dd, J = 6.2, 3.2 Hz, 3H), 7.63 (dd, J = 6.2, 3.1 Hz, 3H), 4.78 (s, 2H), 4.64 (s, 2H), 3.72 , J = 7.6 Hz, 6H) HPLCMS (Method B): [m/z]: 408.2 [M+H]+General procedure: 2-(2-Aminoethyl)-N-[(3-fluoropyridin-2-yl)methyl]-1 , 3-thiazole-4-carboxamide dihydrochloride (103) (2.0 g, 3.96 mmol) was added to a solution of 2-(2-chloroethyl)-1 H-1 , 3-benzodiazole hydrochbride (1.12 g, 5.15 mmol) and DIPEA (10.6 ml, 59.45 mmol) in DMF (60 ml). The reaction mixture was allowed to stir at 3GC for 6 d (reaction was monitored by LCMS). The mixture was concentrated in vacuo and the residue was neutralised using sat. NaHC03 (aq). The aqueous layer was extracted using 4: 1 CHCb / 1 PA (4 x 100 ml) and the combined organic layers were dried (MgS04), filtered and evaporated in vacuo. The crude residue was purified by flash column chromatography (kp-NH, eluting with a gradient of 60-100% EtOAc / heptane followed by 0-20% MeOH / EtOAc) follow by neutral reverse-phase column chromatography (gradient elution 0-60% MeCN / water) to give the title compound (0.173 g, 10%) as a yellow oil. 1 H-NMR (Methanol-d4, 500 MHz): d[ppm]= 8.31 (d, J = 4.6 Hz, 1 H), 8.02 (s, 1 H), 7.57 (t, J = 9.1 Hz, 1 H), 7.45 - 7.40 (m, 2H), 7.36 (dd, J = 8.6, 4.3 Hz, 1 H), 7.17 (dd, J = 6.0, 3.2 Hz, 2H), 4.68 (s, 2H), 3.26 (d, J = 6.8 Hz, 2H), 3.15 - 3.07 (m, 6H) HPLCMS (Method D): [m/z]: 425.1 [M+H]+In a similar fashion to general procedure 7, 2-(2-aminoethyl)-N-(pyridin-2-ylmethyl)-1 , 3-thiazole-4- carboxamide dihydrochloride (105) (240 mg, 0.72 mmol), 2-(2-chloroethyl)-1 H-1 , 3-benzodiazole (259 mg, 1 .43 mmol) and DIPEA (2.17 ml, 12.53 mmol) in DMF (10 ml) afforded the title compound (64 mg, 22%) as a brown solid after purification by basic prep-HPLC followed by flash column chromatography (eluting with a gradient of 0-10% MeOH / DCM followed by 0.8 M ammonia in MeOH / DCM) 1 H-NMR (DMSO-d6, 500 MHz): d[ppm]= 8.87 (t, J = 6.0 Hz, 1 H), 8.50 (d, J = 4.6 Hz, 1 H), 8.10 (s, 1 H), 7.74 (td, J = 7.7, 1 .7 Hz, 1 H), 7.44 (s, 2H), 7.33 - 7.21 (m, 2H), 7.10 (dd , J = 5.9, 3.2 Hz, 2H), 4.55 (d , J = 6.0 Hz, 2H), 3.15 (t, J = 6.7 Hz, 2H), 3.02 (t, J = 6.7 Hz, 2H), 2.90 - 2.96 (m, 4H) HPLCMS (Method G): [m/z]: 407.2 [M+H]+

Molecular Weight:180.63
XLogP3:2.2
Hydrogen Bond Donor Count:1
Hydrogen Bond Acceptor Count:1
Rotatable Bond Count:2
Exact Mass:180.0454260
Monoisotopic Mass:180.0454260
Topological Polar Surface Area:28.7
Heavy Atom Count:12
Complexity:152
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes